Gut microbiota changes after metabolic surgery in adult diabetic patients with mild obesity: a randomised controlled trial
Open Access
- 21 May 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetology & Metabolic Syndrome
- Vol. 13 (1), 1-15
- https://doi.org/10.1186/s13098-021-00672-1
Abstract
Roux-en-Y gastric bypass (RYGB) surgery is one of the most efficient procedures for the treatment of obesity, also improving metabolic and inflammatory status, in patients with mild obesity. The underlying mechanisms have not been fully understood, but gut microbiota is hypothesized to play a key role. Our aim was to evaluate the association between gut microbiota changes and anthropometric, metabolic and inflammatory profiles after metabolic surgery compared with medical therapy, in type 2 diabetic (T2DM) adults with mild obesity (BMI 30–35 kg/m2). DM2 was an open-label, randomised controlled clinical trial (RCT: ISRCTN53984585) with 2 arms: (i) surgical, and (ii) medical. The main outcome was gut microbiota changes after: metabolic surgery (Roux-en-Y gastric bypass—RYGB) versus standard medical therapy. Secondary outcomes included anthropometric, metabolic and inflammatory profiles. Clinical visits, blood workup, and stool samples were collected at baseline and months (M)1, 3, 6, 12. Gut microbiota was profiled using 16S rRNA targeted sequencing. Twenty patients were included: 10 in surgical and 10 in medical arm. Anthropometric and metabolic comparative analysis favoured RYGB over medical arm. At M12, the percentage of weight loss was 25.5 vs. 4.9% (p < 0.001) and HbA1c was 6.2 vs. 7.7% (p < 0.001) respectively. We observed a continuous increase of genus richness after RYGB up until M12. In the medical arm, genus richness ended-up being significantly lower at M12. Composition analysis indicated significant changes of the overall microbial ecosystem (permanova p = 0.004, [R2 = 0.17]) during the follow-up period after RYGB. There was a strong association between improvement of anthropometric/metabolic/inflammatory biomarkers and increase in microbial richness and Proteobacterial lineages. This was the first RCT studying composite clinical, analytic, and microbiome changes in T2DM patients with class 1 obesity after RYGB versus standard medical therapy. The remarkable phenotypic improvement after surgery occurred concomitantly with changes in the gut microbiome, but at a lower level. Trial registration: ISRCTN53984585Keywords
This publication has 55 references indexed in Scilit:
- Conserved Shifts in the Gut Microbiota Due to Gastric Bypass Reduce Host Weight and AdiposityScience Translational Medicine, 2013
- A Guide to Enterotypes across the Human Body: Meta-Analysis of Microbial Community Structures in Human Microbiome DatasetsPLoS Computational Biology, 2013
- Evaluation of general 16S ribosomal RNA gene PCR primers for classical and next-generation sequencing-based diversity studiesNucleic Acids Research, 2012
- Bariatric Surgery versus Intensive Medical Therapy in Obese Patients with DiabetesThe New England Journal of Medicine, 2012
- Gut Microbiota in Human Adults with Type 2 Diabetes Differs from Non-Diabetic AdultsPLOS ONE, 2010
- Human gut microbiome adopts an alternative state following small bowel transplantationProceedings of the National Academy of Sciences of the United States of America, 2009
- Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeabilityGut, 2009
- Human gut microbiota in obesity and after gastric bypassProceedings of the National Academy of Sciences of the United States of America, 2009
- Human gut microbes associated with obesityNature, 2006
- Obesity alters gut microbial ecologyProceedings of the National Academy of Sciences of the United States of America, 2005